We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
-14.6%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$68.5B
AUM Growth
-$9.16B
Cap. Flow
+$4.06B
Cap. Flow %
5.93%
Top 10 Hldgs %
21.45%
Holding
3,375
New
359
Increased
2,433
Reduced
285
Closed
282

Top Buys

Rank Stock Value
1
LIN icon
Linde
LIN
+$124M
2
AAPL icon
Apple
AAPL
+$110M
3
MSFT icon
Microsoft
MSFT
+$104M
4
AMZN icon
Amazon
AMZN
+$71.3M
5
WBD icon
Warner Bros
WBD
+$69.6M

Top Sells

Rank Stock Value
1
T icon
AT&T
T
+$61.6M
2
CERN
Cerner Corp
CERN
+$50.9M
3
NXPI icon
NXP Semiconductors
NXPI
+$31.4M
4
AZPN
ASPEN TECHNOLOGY INC
AZPN
+$30.4M
5
YUMC icon
Yum China
YUMC
+$16.3M

Sector Composition

Rank Sector Weight
1 Technology 23.13%
2 Healthcare 14.42%
3 Financials 13.45%
4 Consumer Discretionary 10.49%
5 Industrials 9.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARDX icon
3101
Ardelyx
ARDX
$1.2B
-97,981
Closed -$105K
ATOS icon
3102
Atossa Therapeutics
ATOS
$24.1M
-9,460
Closed -$177K
AVTX icon
3103
Avalo Therapeutics
AVTX
$989M
-17
Closed -$36K
AXDX
3104
DELISTED
Accelerate Diagnostics
AXDX
-3,576
Closed -$51K
BAP icon
3105
Credicorp
BAP
$31.2B
-1,362
Closed -$234K
BCAB icon
3106
BioAtla
BCAB
$5.53M
-291
Closed -$73K
BDTX icon
3107
Black Diamond Therapeutics
BDTX
$110M
-29,064
Closed -$81K
BMEA icon
3108
Biomea Fusion
BMEA
$90.4M
-13,190
Closed -$59K
BNED icon
3109
Barnes & Noble Education
BNED
$438M
-1,054
Closed -$377K
BOLT icon
3110
Bolt Biotherapeutics
BOLT
$7.44M
-1,183
Closed -$65K
BYRN icon
3111
Byrna Technologies
BYRN
$98.9M
-16,877
Closed -$138K
BYSI icon
3112
BeyondSpring
BYSI
$35.8M
-20,091
Closed -$44K
CARM
3113
DELISTED
Carisma Therapeutics
CARM
-7,480
Closed -$90K
CDZI icon
3114
Cadiz
CDZI
$275M
-29,369
Closed -$61K
CECO icon
3115
Ceco Environmental
CECO
$4.01B
-40,918
Closed -$225K
CIA icon
3116
Citizens
CIA
$231M
-67,246
Closed -$285K
CLNN icon
3117
Clene
CLNN
$68.2M
-846
Closed -$67K
CLPT icon
3118
ClearPoint Neuro
CLPT
$408M
-17,681
Closed -$184K
CPS icon
3119
Cooper-Standard Automotive
CPS
$491M
-23,006
Closed -$202K
CRDF icon
3120
Cardiff Oncology
CRDF
$74.7M
-46,290
Closed -$115K
CRIS icon
3121
Curis
CRIS
$8.59M
-229
Closed -$218K
CRMD icon
3122
CorMedix
CRMD
$589M
-42,331
Closed -$232K
CTMX icon
3123
CytomX Therapeutics
CTMX
$734M
-67,376
Closed -$180K
CTSO icon
3124
Cytosorbents Corp
CTSO
$25M
-40,176
Closed -$128K
CTXR icon
3125
Citius Pharmaceuticals
CTXR
$17.6M
-4,992
Closed -$223K

Similar funds

RhumbLine Advisers's Q2 2022 Portfolio in Review

As of Q2 2022, RhumbLine Advisers held 3,375 positions worth $68.5B, down 12% from $77.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

RhumbLine Advisers deployed $4.06B of net new capital in Q2 2022, opening 359 new positions and adding to 2,433 existing holdings. Its largest new stake was Aspen Technology Inc: 81,883 shares worth $15M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was AT&T, an estimated $61.6M trimmed.

  • RhumbLine Advisers's largest Q2 2022 buy was Aspen Technology Inc: 81,883 shares worth $15M.
  • RhumbLine Advisers added most to Linde in Q2 2022, an estimated $124M increase.
  • RhumbLine Advisers's biggest Q2 2022 reduction was AT&T, cutting an estimated $61.6M.
  • RhumbLine Advisers fully exited Cerner Corp in Q2 2022, selling an estimated $50.9M.
  • RhumbLine Advisers's ten largest holdings make up 21% of its $68.5B portfolio in Q2 2022.
  • RhumbLine Advisers opened 359 new positions and closed 282 in Q2 2022.
  • RhumbLine Advisers's portfolio value fell 12% quarter-over-quarter to $68.5B.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.